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Care on prevention and treatment of rare (orphan) diseases’ has been recently 
issued. It governs the measures of OD prophylaxis. Methods: According to the 
Law, in order to improve OD patient care, a work on medical and technological docu-
ments on such topics as mucopolysaccharidosis, Gaucher disease, phenylketonuria, 
hemophilia was launched. The development of medico-technological documents 
was done in a few steps. Firstly, the search for clinical guidelines was conducted 
in the GIN library and other sources. Secondly, the primary selection and appraisal 
with AGREE II instrument have been carried out. The next step was adaptation of 
clinical guidelines and development of clinical protocols of the medical care. It 
was conducted by multidisciplinary working groups including leading specialists 
in clinical genetics, health care managers and patients organizations. Results: 
Today the clinical protocols of treatment of mucopolysaccharidosis patients, based 
on evidence of the effectiveness of medical technologies, pharmacotherapy and 
organizational principles of its provision, were approved. The documents contained 
modern approaches for diagnostics and treatment of mucopolysaccharidosis, which 
are ajusted to the health care system of Ukraine. ConClusions: Harmonization 
of treatment practices of OD in Ukraine with international best practice will bring 
the treatment of these states in Ukraine to a new level and provide thorough meas-
ures aimed at the development of screening and prevention programs, diagnostics 
and treatment, as well network collaboration among health services, educational 
institutions, public etc.
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objeCtives: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder 
that can cause multi-organ damage, leading to reduced life expectancy, lower qual-
ity of life, and high medical expenditures. Therefore, long-term and comprehensive 
disease management and monitoring are important. This study aimed to examine 
treatment pattern, quality of SLE care, and utilization and costs of medical care of 
SLE patients. Methods: The National Health Insurance Research Database was 
adopted to identify patients diagnosed with SLE before 2010 through their eligibility 
for catastrophic illness of SLE, and examine their use and costs of health services 
in 2010. Logistic regression models and generalized linear models were adopted 
for analyses. Results: The majority of 744 patients with SLE was female (85%), 
older than 40 years old (54%), and having been diagnosed with SLE for more than 
five years (68%). Sixty-one percent of them received corticosteroids, 59% received 
antimalarials, and 36% received immunosupressants. Annual tests for complete 
blood count, creatinine, and serum levels of complement component C3/C4 and 
anti-dsDNA antibodies were received by 85%, 78%, and 76% of the subjects, respec-
tively. Forty-four percent of them received annual evaluation of cardiovascular risk, 
and 3% of them received influenza vaccination. Average number of outpatient visit 
was 33.47, and SLL-related visit was 12.82. Twenty-two percent of them were admit-
ted to hospital during the year, and the average number of hospital admission was 
0.48. The average annual medical cost was NTD105,059, and the average SLE-related 
medical cost was NTD29,770. Shorter time since SLE diagnosis was associated with 
more intense treatment, better adherence to recommendations for annual tests, and 
higher SLE-related costs. ConClusions: This study identified treatment pattern, 
quality of SLE care, and use and costs of patients with SLE. Disease management 
and monitoring need to be improved.
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objeCtives: To investigate the global perspectives of Turkish Rheumatologists 
regarding expected FMF prevalence, undiagnosed patients ratio, arguments in diag-
nostic procedure and management of FMF. Methods: A questionnaire consist of 
estimated frequency, diagnostic modalities and follow up characteristics in addition 
to therapeutic approach was set up. Even though a regular colchicine use, ≥ 1 attack /
month during 6 months was accepted as colchicine resistant. All members of Turkey 
Society for Rheumatology from country wide (n= 235) were invited to fill in the 
web-based questionnaire for FMF by e-mail. Totally 108 members (45.9%) answered 
the questionnaire. Results: Estimated prevalence was median 0.2% (IQR25-75: 
0.1-0.7) for FMF. Only 51.4±19.0 % of these patients had been diagnosed according 
to Rheumatologists opinion. Time to diagnosis from the first symptom was more 
than 3 years in 49.5% of patients. Description of typical attacks in anamnesis is the 
most frequent parameter in diagnosis of patients whereas in 26.7 %of patients MEFV 
mutations were required for diagnosis. 53.5 ±21.3 % of patients were on regular 
follow up and 75.7% of these follow up was with a 3-6 months period. Frequency 
of Colchicine resistant patients was expected in 7.2%. The use of biologic agents in 
the patients followed up by these physicians was expected as 3.4%. ConClusions: 
Since half of the estimated prevalence was expected as undiagnosed and patients 
have a 3-years delay in diagnosis, Medical and Social Activities are required to 
increase the awareness of FMF. Less than 5 percent of patients required biologic 
agents in FMF.
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observed for age, pharmacologic treatment and disease severity. No significant 
statistical effect was observed for gender, late onset patients (> 50 years) and liver 
transplant. ConClusions: The preference-based utility measures used in this 
study adequately disentangle TTR-FAP impact on patient’s quality of life and allow 
discriminating across different TTR-FAP clinical severity states, interventions and 
demographic characteristics. Assuming that these values represent the patients’ 
preferences and the utility associated with their health state, the results presented 
in this study may be used in future health technologies cost-utility studies.
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objeCtives: Immune thrombocytopenia (ITP) is associated with a risk of spontane-
ous and excessive bleeding. Among the treatment options are medical therapies and 
splenectomy – a major intervention with lifelong consequences for the patient. Both 
ITP and ITP-treatment may impact health-related quality of life (HrQoL); therefore, 
a literature search was conducted to assess HrQoL of splenectomized compared to 
non-splenectomized ITP patients. Methods: A targeted literature search was con-
ducted via Ovid (Medline, Embase, and Cochrane) in September 2014. Search strings 
were based on PICO-criteria (Patient, Intervention, Comparison and Outcomes). 
Inclusion criteria were: studies of adult patients with ITP that contained information 
on HrQoL; clinical trials, RCTs, meta-analyses, observational trials, retrospective 
studies or systematic reviews; manuscripts and congress abstracts in English or 
German language. Results: The search identified 148 potentially relevant publica-
tions. After removing duplicates, 120 titles and abstracts were screened. Following 
the title/abstract screening, a full text screening (n= 21) identified six relevant pub-
lications. HrQoL was assessed in these six publications using generic (SF-36, n= 2; 
EQ-5D, n= 1) and disease-specifc (ITP-PAQ, n= 4) instruments. Two studies using 
generic instruments reported no difference in HrQoL between splenectomized and 
non-splenectomized patients. Of the four studies using the ITP-PAQ, two reported 
no difference and two found worse HrQoL in splenectomized versus non-splenec-
tomized patients. In the only study that included both generic (SF-36, EQ-5D) and 
ITP-specific measures, results were inconsistent, as they varied in outcomes. Overall 
detailed results were not always provided and HrQoL was not reported according 
to response to therapy in any study. ConClusions: The impact of splenectomy 
on HrQoL in patients with ITP is inconclusive and inconsistently reported in the 
literature, due to use of different instruments, diverse patient characteristics, and 
pooling of data among responding and non-responding patients. Further studies are 
needed to address this question within clearly-defined populations.
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objeCtives: Treatment for children with GHD involves daily injections which 
may begin at a very early age and continue throughout childhood. However, the 
treatment burden (TB) for children and their parents has not been examined. The 
purpose of this study was to support the content validity of a new GHD-specific TB 
measure, with versions for patient-reported outcome (PRO) for older children, and 
observer-reported outcome (ObsRO) and PRO for parents/guardians. Methods: 
Focus groups and interviews were conducted with 39 children (aged 8–12) with 
GHD, 31 parents of children (aged 4–12) and eight clinical experts in three countries 
(Germany, UK, US). Interviews were analysed and coded using adapted grounded 
theory. A conceptual model of TB was developed and items were generated and 
then cognitively debriefed. Results: Qualitative analysis found saturation was 
reached with three domains for child TB and two domains for parent TB. Child 
domains (and major proximal subdomains) were: Physical (pain, 33% and bruis-
ing, 19%), Interference (Interference with overnight or other activities, 29% and 
Time needed emotionally to prepare for treatment, 23%) and Emotional (Worry, 
about injections, 37%, Unhappiness with injection frequency, 25%, and Fear, 22%). 
Parent TB domains were Emotional (Worry or anxiety about treatment or treat-
ment administration, 58% and Worry about causing pain, 42%) and Interference 
(Time spent preparing and administering injection, 42%, Interference with travel/
vacation, 42%, and Interference with daily/family routines, 35%). The items were 
cognitively debriefed in a new sample (N= 26: 13 children, 13 parents) and, based on 
findings, it was determined that the PRO version was appropriate for children aged 
9–12. The final measure includes 17 items (child PRO and parent ObsRO versions) 
with a 12-item parent PRO module. ConClusions: The conceptual validity of the 
TB-CGHD is supported by these qualitative findings and the measure is now ready 
for psychometric validation.
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objeCtives: There is no integrated approach to the problem of orphan diseases 
(OD) in Ukraine. Diagnosis of these illnesses is often complicated and delayed, the 
treatment is often ineffective because of the lack and unavailability of essential 
medicines and methods of treatment, the quality of life for most patients remains 
poor. The Law of Ukraine ‘On amendments to the Basic Laws of Ukraine on Health 
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drugs across ATC groups appeared to differ between the EMA and FDA suggesting 
the regulatory bodies may have different preferences with regard to research and 
development in the various therapeutic fields.
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bACkgRound: In Russia all drugs for state medical organisations and programs 
are purchased through public tenders in order to enhance competition, decrease 
price and prevent corruption. Drugs for rare diseases (DRD) are often produced by 
the only manufacturer thus being monopolistic. There is lack of information about 
the effectiveness of tender procedures for DRD in real life. objeCtives: To assess 
the competition in public procurement of DRD and effectiveness of tender proce-
dures. Methods: The analysis was conducted on the basis of 1499 selected trade 
procedures on DRD procurement in 2013. We evaluated the proportion of procedures 
that have passed with the only one participant, the level of price reduction resulted 
from trading, the amount and volume of purchases of DRD in the subjects of the 
Russian Federation. Data on drug procurement procedures were obtained from the 
official website of state purchases www.zakupki.gov.ru. Data collection and process-
ing were performed using the program Microsoft EXCEL and Statistica 6.1. Results: 
Total amount of spending for DRD in 2013 was € 192.23 million, with declared pro-
cedures on € 197.93 million. Competition was absent in 592 (74.47%) procedures of 
monopolistic drugs procurement. 75% of tenders were performed without reduc-
ing the price. There were € 5.69 million savings generated by purchases (3% of the 
amount of declared procedures). ConClusions: Tender procedures used for the 
procurement of monopoly drugs are ineffective because of the lack of competition; 
distributors are not interested in price reduction at noncompetitive procedures.
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objeCtives: The objective of this study is to analyze and compare the recom-
mendation made by several countries for orphan drugs such as Canada, Scotland, 
Australia, France and England.The study will try to address solutions and innovative 
ways to evaluate orphan drugs from an economic perspective and try to propose 
the hallmarks of an ideal policy to be implemented. Methods: The Orphanet 
website was screened to find orphan drugs with national designations.237 orphan 
drugs indication were retrieved and 36 technologies were included in the study and 
stratified by therapeutic areas.In total, 180 recommendations were analyzed for the 
5 included HTA agencies. Each recommendation was analyzed for the following 
parameters: Listing, clinical recommendation, economic recommendation, QALYs 
and rarity of disease taken in consideration. Results: Scotland (88%) was the coun-
try that took the most in consideration the orphan designation of drugs, followed by 
France (74%) and Australia (45%). In addition, France and Scotland were the 2 coun-
tries that had the most positive listings (with criteria or without). The clinical benefit 
was demonstrated in multiple drugs throughout the different agencies. However, the 
economic part was very heterogeneous. Scotland issued a lot of positive economic 
recommendations (60%); however countries such as Canada had a very low percent-
age of economic being accepted (19%). QALYs did not seem to correlate with the type 
of listing.Countries that had the most health policies regarding orphan drugs had 
a better rate of orphan drugs being accepted for reimbursement. ConClusions: 
Though there are certain similarities across countries with regards to the HTA of 
orphan drugs, significant differences exist, which are likely to continue to cause 
variations in access to orphan drugs across countries. Positive listing by CADTH was 
one of the lowest between 5 countries and the economic recommendations were 
the most negative in Canada.Seperate funding for orphan drugs and specific clinical 
assessment should idealy be implemented throughout the world.
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objeCtives: Since the introduction of the European rare diseases policy in 2000, 82 
drugs have received orphan status. As the orphan drug market is rapidly expanding, 
this number is expected to increase. The research objective was to identify how 
European countries manage the increase in available orphan drugs and whether 
there are similarities or differences in orphan drug reimbursement policies across 
Europe. Methods: We assessed orphan drug policies in 16 European countries, 
grouped into four archetypes: health insurance markets (Austria, Belgium, France, 
Germany, The Netherlands, Switzerland); devolved markets (Italy, Spain); health eco-
nomic markets (Ireland, Portugal, UK); Nordic country markets (Denmark, Norway, 
Sweden). Policies were assessed considering five key factors: key stakeholders; 
treatment setting; evidence requirements; reimbursement processes; source of 
funding. Results: In all country archetypes, except Nordic markets, the reimburse-
ment assessment of orphan drugs used for in- and out-patient care is the same. 
All archetypes, except health insurance markets, follow the same processes for 
orphan and non-orphan drugs. Although in Scotland and England, drugs classified 
as ultra-orphan go through specialised processes. In devolved markets, economic 
and clinical data are considered; in health insurance markets, economic data are 
only considered under certain circumstances in some countries. Nordic countries 
have fewer evidence requirements than other archetypes. In both health economic 
and health insurance markets, orphan drug funding varies with treatment setting. 
objeCtives: Anemia affects about 25% of the world population and is the second 
main cause of incapacity worldwide. Clinical guidelines recommend upfront use 
of iron (oral or intravenous, IV) to correct iron deficiency anemia (IDA) instead of 
blood transfusion (BT). Nonetheless, utilization of BT is a common practice fre-
quently associated with clinical complications and high economic burden. Our 
main objective was to estimate the impact of BT in hospital length of stay (LOS) 
and in intra- and extra-hospital mortality of patients with IDA. Methods: This 
was a non-interventional, retrospective, single-center study. A convenience sam-
ple composed of 196 IDA patients treated with IV iron during 2013 was analyzed. 
Data was retrieved from patients’ clinical and pharmacy records. Between-group 
comparisons were performed using non-parametric methods (Mann-Whitney-
Wilcoxon and Kruskal Wallis). Logistic regression models were estimated to assess 
the odds of intra-hospital mortality. Kaplan-Meier survival estimates and Peto test 
were used to assess survival after hospital discharge (extra-hospital mortality). A 
5% significance level was adopted. Results: Here we present the results of the 
subset of 136 hospitalized patients, mean (SD) age of 68.6 (18.7) years and 50.7% 
males, corresponding to 148 hospitalization episodes. In 62.2% of these episodes 
at least 1BT was performed. Mean LOS was significantly higher in patients with 
BT (29.2 versus 15.3 days; p-value< 0.0001). The odds ratio of dying during hospi-
talization in patients with > 2BT was 3.73 (95%CI: 1.01-13.74) when compared to 
patients with ≤ 2BT, adjusting for age, sex, surgery or iron IV utilization. We observed 
a higher extra-hospital mortality in BT patients although not statistically significant 
(p-value= 0.118), probably due to the low number of patients with follow-up data 
(n= 33). ConClusions: Blood transfusions result in higher hospital length of stay 
and mortality. A better patient blood-management may improve patient outcomes 
and provide a more efficient use of health resources.
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objeCtives: Current validated DAIs in SLE require disease expertise and/or 
involve complex scoring systems, and are often impractical for use in daily clini-
cal practice. To address this, several new simplified DAIs in SLE are in different 
stages of development, including SLE Activity Tracking Evaluation Tool (LAST:14 
items; includes medications, Physician Global Assessment (PhGA) 0-10 scale, Patient 
Global Assessment (PtGA:0-10), C3, C4 & anti-dsDNA lab measures), Clinical LAST 
(C-LAST:11 items; similar to LAST, without lab measures), Total Lupus Activity Score 
(TLAS:30 items; includes 15 physician clinical assessments and 15 patient self-
assessment of symptoms), and Simple Disease Assessment for People with Lupus 
Erythematosus (SIMPLE:17 items; includes patient self-assessment of symptoms, 
Lupus Impact Tracker, steroid medication, C3, C4 & proteinuria). The primary objec-
tive of this analysis is to assess the convergent validity of these various tools as 
well as PhGA indices in relation to SLEDAI-2K. Methods: This is a prospective real-
world observational cohort study of SLE patients receiving standard care in 2 private 
and 2 academic sites in the US. Respective portions of DAIs are completed by physi-
cians and patients at four timepoints: baseline/3mo/6mo/12mo. DAI completions: 
SLEDAI-2K:201; TLAS/SIMPLE: approx. 152; LAST/C-LAST:168. Pearson correlation 
coefficient (r) was computed comparing mean SLEDAI-2K score to other DAI scores 
at baseline. Results: 201 SLE patients were enrolled (mean age:45yrs; female:91%; 
Black/African-American (AA):56%; Hispanic:10%). At baseline, mean SLEDAI-2K score 
was 3.4 (SD:3.2); each of the DAIs had statistically significant positive correlation 
with the SLEDAI-2K: LAST (r= 0.566/p< 0.0001), PhGA:0-10 scale (r= 0.563/p< 0.0001), 
SIMPLE (r= 0.560/p< 0.0001), PhGA:0-3 scale (r= 0.553/p< 0.0001), C-LAST (r= 0.450/
p< 0.0001) and TLAS (r= 0.348/p< 0.0001). Analysis stratified by AA and non-AA sta-
tus revealed similarly significant correlations between SLEDAI-2K and the other 
DAIs. ConClusions: In this cross-sectional analysis, each of the studied DAIs 
appeared to have convergent validity with the SLEDAI-2K. Further analyses with 
longitudinal data will assess additional psychometric properties of the instruments.
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objeCtives: Developing innovative treatments for rare diseases is intrinsically 
difficult due to small patient population sizes and the scarcity of high quality evi-
dence. Orphan drug designation is attributed to drugs which have been developed 
to treat rare diseases; however, the European Medicines Agency (EMA) and US Food 
and Drug Administration (FDA) define rare diseases differently. The objective of this 
study was therefore to investigate the number and type of orphan drug designations 
across the EMA and FDA. Methods: Data on authorised drugs awarded orphan 
status by the EMA and FDA is freely available and was obtained from their respec-
tive websites. Authorised orphan drugs were analysed dating back to the first EMA 
orphan drug designation in 2002. Results: The EMA designated 82 drugs orphan 
status, whilst the FDA designated 170 drugs orphan status. An upward trend in 
the number of drugs designated orphan status by the EMA was observed, whilst 
a downward trend was present in FDA orphan designations. The distribution of 
orphan drugs across WHO Anatomical Therapeutic Chemical (ATC) classifications 
appears to vary, for instance: 18% of EMA authorised orphan drugs were in the 
alimentary tract and metabolism group (ATC code A), compared to just 6% of FDA 
orphan drugs. Conversely, orphan drugs in the blood and blood forming organs 
category (ATC code B) comprised 2% of EMA authorised orphan drugs compared 
to 12% with the FDA. ConClusions: The EMA has designated half the number of 
drugs orphan status compared to the FDA however the number of authorised drugs 
designated orphan status appears to be on the rise in Europe. The pattern of orphan 
